Steroid hormone receptors in breast cancer management

Breast Cancer Research and Treatment

Volumn 51, Issue 3, 1998, Pages 227-238

  Osborne, C Kent ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Breast cancer; Estrogen receptors; Hormone therapy; Progesterone receptors; Prognosis

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; TUMOR DIFFERENTIATION;

BREAST NEOPLASMS; FEMALE; HORMONE ANTAGONISTS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032423729     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006132427948     Document Type: Review

References (76)

1. Jensen EV, DeSombre ER: Mechanism of action of the female sex hormones. Annu Rev Biochem 41:203-230, 1972
2. Gorski J, Toft DO, Shyamala G, Smith D, Notides A: Hormone receptors: Studies on the interaction of estrogen with uterus. Recent Prog Horm Res 24:45-80, 1968
3. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884-2888, 1980
4. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2:1102-1109, 1984
5. Glass GK, Rose DW, Rosenfeld MG: Nuclear receptor coactivators. Curr Opin Cell Biol 9:222-232, 1997
6. Osborne CK, Elledge RM, Fuqua SAW: Estrogen receptors in breast cancer therapy. Sci Med 3:32-41, 1996
7. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167-1177, 1996
8. Anzick AL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan X-Y, Sauter G, Kallioniemi O-P, Trent JM, Meltzer PS: AIBI, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968, 1997
9. Hörlein AJ, Näär AM, Helnzel T, Tochia J, Gloss B, Kurokawa R, Ryan A, Kamel Y, Söderström M, Glass CK, Rosenfeld MG: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404, 1995
10. Li H, Leo C, Schroen DJ, Chen JD: Characterization of receptor interaction and transcriptional repression by the corepressor SMRT. Mol Endocrinol 11:2025-2037, 1997
11. Nagy L, Kao H-Y, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380, 1997
12. Jackson WA, Richer RK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693-705, 1997
13. Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666, 1997
14. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95, 1994
15. Webb P, Lopez GN, Uht RM, Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443-456, 1995
16. Kuiper GG, Enmark E, Pelto-Huikko P, Nilsson S, Gustafsson JA: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930, 1996
17. Mosselman S, Polman J, Dijkema R: ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53, 1996
18. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870, 1997
19. Montano MM, Muller V, Trobaugh A, Katzenellenbogen BS: The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814-825, 1995
20. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V: Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol Endocrinol 11:353-365, 1997
21. Dotzlaw H, Leygue E, Watson PH, Murphy LC: Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 82:2371-2374, 1997
22. Cowley SM, Hoare S, Mosselman S, Parker MG: Estrogen receptors α and β form heterodimers on DNA. J Biol Chem 272:19858-19862, 1997
23. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-A, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508-1510, 1997
24. Osborne CK: Receptors. In: Harris J, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases, 2d Edition. JB Lippincott Co, Philadelphia PA, 1991, pp 301-325
25. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413-416, 1983
26. Green GL, Sobel NB, King WJ, Jensen EV: Immunochemical studies of estrogen receptors. J Steroid Biochem 20:51-56, 1984
27. King WJ, Green GL: Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307:745-747, 1984.
28. McGuire WL, Vollmer EP, Carbone PP (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975
29. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz ABJ: Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125:107-113, 1990
30. Millis RR: Correlation of hormone receptors with pathological features in human breast cancer. Cancer 46:2869-2871, 1980
31. Fisher ER, Osborne CK, McGuire WL, Redmond C, Knight WA, Fisher B, Bannayan G, Walder A, Jacobson AA, Queen DM, Bennett DE, Ford HC: Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat 1:37-41, 1981
32. Maynard PV, Davies CJ, Blamey RW, Elston CW, Johnson J, Griffiths K: Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer 38:745-748, 1978
33. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B: Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45:349-353, 1980
34. Glaubitz LC, Bowen JH, Cox EB, McCarty KS: Elastosis in human breast cancer. Correlation with sex steroid receptors and comparison with clinical outcome. Arch Pathol Lab Med 108:27-30, 1984
35. Meyer JS, Rao BR, Stevens SC, White WL: Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer 40:2290-2298, 1977
36. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9-20, 1993
37. Walt AJ, Singhakowinta A, Brooks SC, Cortez A: The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery 80:506-512, 1976
38. Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977
39. Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R: Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 63:1271-1277, 1979
40. Westerberg H, Gustafson SA, Nordenskjold B, Silfversward C, Wallgren A: Estrogen receptor level and other factors in early recurrence of breast cancer. Int J Cancer 26:429-433, 1980
41. Bishop HM, Blamey RW, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship of oestrogen-receptor status to survival in breast cancer. Lancet 2:283-284, 1979
42. Nicholson RI, Campbell FC, Blamey RW, Elston CW, George D, Griffiths K: Steroid receptors in early breast cancer: Value in prognosis. J Steroid Biochem 15:193-199, 1981
43. Crowe JP, Hubay CA, Pearson OH, Marshall JS, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, McGuire WL: Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2:171-176, 1982
44. Aamdal S, Bormer O, Jorgensen O, Host H, Eliassen G, Kaalhus O, Pihl A: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53:2525-2529, 1984
45. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671-675, 1979
46. Hilsenbeck SG, Ravdin PM, de Moor C, Osborne CK, Clark GM: Paradoxical decreases in prognostic utility as datasets mature: Time-dependent lack of proportional hazards in prognostic factors in primary breast cancer. Breast Cancer Res Treat 37 (suppl):35, 1996
47. Lippman ME, Allegra JC: Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46:2829-2834, 1980
48. Paridaens R, Sylvester RJ, Ferrazzi E, Legros N, Leclercq G, Heuson JC: Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46:2889-2895, 1980
49. Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Griffiths K, Haybittle JL: Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 2:1317-1319, 1981
50. Knight WA, Osborne CK, McGuire WL: Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 9:361-368, 1980
51. Osborne CK, Clark GM, Ravdin PM: Adjuvant systemic therapy of primary breast cancer. In: Harris JR, Lippman ME, Hellman S (eds) Diseases of the Breast. Lippincott-Raven Publishers, Philadelphia PA, 1996, pp 546-576
52. NATO Steering Committee: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57:608-611, 1988
53. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office, Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet 2:171-175, 1987
54. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA, and other NSABP investigators: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4:459-471, 1986
55. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, in press
56. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by presence of in-situ carcinoma. J Clin Oncol 10:599-605, 1992
57. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
58. Seidman AD, Baselga J, Yao T-J, Gilewski T, Rosen PP: HER-2/neu overexpression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer (Abstract 80). Proc Am Soc Clin Oncol 15:104, 1996
59. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
60. Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330-1334, 1978
61. Clarke CL, Balleine RL, Auchus RJ, Fuqua SAW: Estrogen and progesterone receptor variants in human breast cancer. Current Opin Endocrinol Diabetes 2:398-403, 1995
62. Fuqua SAW: Estrogen and progesterone receptors and breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven Publishers, Philadelphia PA, 1996, pp 261-271
63. Lehrer SP, Schmutzler RK, Rabin JM, Schachter BS: An estrogen receptor genetic polymorphism and a history of spontaneous abortion: correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer. Breast Cancer Res Treat 26:175-180, 1993
64. Karnick PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54:349-353, 1994
65. Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast cancer. Cancer Res 52:483-486, 1992
66. Zhang Q, Borg A, Fuqua SAW: An exon 5 deletion variant of the estrogen receptor frequently co-expressed with wild-type estrogen receptor in human breast cancer. Cancer Res 53:5882-5884, 1993
67. Fuqua SAW, Wiltschke C, Castles C, Wolf D, Allred DC: A role for estrogen receptor variants in endocrine resistance. Endocrine-Related Cancer 2:19-25, 1995
68. Wiltschke C, Lemieux P, Wolf DM, Castles CG, Zhang QX, O'Connell P, Allred DC, Fuqua SAW: Isolation of a super-active estrogen receptor variant from premalignant breast lesions (Abstract). Breast Cancer Res Treat 37 (Suppl):40, 1996
69. Horwitz KB, McGuire WL, Pearson OH, Segaloff A: Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 189:726-727, 1975
70. Gross GE, Clark GM, Chamness GC, McGuire WL: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44:836-840, 1984
71. Ravdin PM, Green S, Melink-Dorr T, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest oncology Group Study. J Clin Oncol 10:1284-1291, 1992
72. Gronemeyer H: Transcription activation by estrogen and progesterone receptors. Ann Rev Genet 25:89-123, 1991
73. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP: The A and B forms of human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14:8356-8364, 1994
74. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB: Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A receptors. Mol Endocrinol 7:1256-1265, 1993
75. McDonnell DP, Goldman ME: RU486 exerts anti-estrogenic activities through a novel progesterone receptor A-form mediated mechanism. J Biol Chem 269:11945-11949, 1994
76. Chalbos D, Galtier F: Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. J Biol Chem 269:23007-23012, 1994